Press Releases

Veeva Announces Digital Trials Platform Connecting Patients, Sites, and Sponsors

Veeva Digital Trials Platform delivers seamless clinical trial execution and data flow across stakeholders

New capabilities advance industry toward patient-centric trials

PLEASANTON, CA — Oct. 12, 2021 — Veeva Systems (NYSE: VEEV) today announced the Veeva Digital Trials Platform, a new solution to significantly advance clinical trial execution by providing a complete and connected technology ecosystem that spans patients, research sites, and trial sponsors. The Veeva Digital Trials Platform is available now for early adopters.

The comprehensive product offering includes the following core solutions:

  • Veeva Vault Clinical Suite, the leading clinical operations and clinical data management technology for sponsors and CROs. Vault Clinical Suite has expanded to include Site Connect and eConsent, which are available today. ePRO, Virtual Visits, eSource, and Sensor Data are planned for future releases.
  • Veeva SiteVault Free, an application for sites to modernize their operations and run connected clinical trials with sponsors using Vault Clinical Suite.
  • MyVeeva for Patients, a single, intuitive application that makes it easy for patients to participate in clinical research.

Each of these solutions are built for the unique needs of patients, sites, and sponsors but connected for seamless execution and flow of data across all stakeholders.

The patient consent process provides a good illustration of how the Veeva Digital Trials Platform drives collaboration and data flow. Using Veeva eConsent, sponsors author and approve a consent form, which flows automatically to sites using Veeva SiteVault Free. Sites can then modify the consent form, obtain IRB approval, and consent patients with the MyVeeva mobile application. The patient status and consent form are immediately available as validated and reportable data for the sponsor in Vault Clinical Suite.

By addressing the life sciences industry’s need for a complete, standardized, and connected solution, the Veeva Digital Trials Platform will deliver faster, more efficient trials with greater data accuracy and increased patient diversity.

“By bringing together the growing community of research sites using Veeva SiteVault Free with sponsors using Vault Clinical Suite, we aim to accelerate the move to digital trial execution,” said Jim Reilly, vice president, Vault R&D at Veeva. “The Veeva Digital Trials Platform will make clinical trials easier and faster for patients, sites, and sponsors.”

Veeva Digital Trials Gaining Early Momentum
Veeva Site Connect, the first new Digital Trials application, transforms information sharing between sites and sponsors from manual, paper-based transfers to an automated, digital exchange. It is now in use by early adopter sponsors, including top 20 pharmas, biotechs, and CROs, like Celerion.

“Celerion is excited to deepen the partnership with Veeva as an early adopter of Veeva Site Connect and Veeva eConsent to transform the experience for sites and patients,” said Julie Saathoff, executive director, Celerion. “We’re conducting about 200 trials a year, so automating the flow of information across stakeholders will help us to significantly streamline operations, improve collaboration, and speed processing. The efficiency gains will allow us to improve patient care and deliver more innovations, faster.”

LEO Pharma recently announced their partnership to adopt the complete Veeva Digital Trials Platform. Building on its success with the Veeva Clinical Operations Suite, LEO Pharma will complete its standardization on existing Veeva clinical technology, be an early adopter of future Veeva solutions, and help to shape the Veeva digital trials roadmap.

“We’ve been exploring ways to transform clinical trials, but COVID-19 sped up this process. By promptly responding to changing market dynamics, we kept our trials going without delay. Partnering with Veeva supports our 2030 strategy as it will help us to bring innovative treatments to patients faster while also supporting a more sustainable business,” said Jörg Möller, executive vice president and head of R&D at LEO Pharma. “Veeva’s track record of product excellence makes it the ideal long-term partner to help us achieve this, enabling us to help patients faster and better.

Learn more at the Veeva R&D and Quality Summit Connect, October 14, 2021. Life sciences professionals can register at

Additional Information
Connect with Veeva on LinkedIn:
Follow @veevasystems on Twitter:

About Veeva Systems
Veeva is the global leader in cloud software for the life sciences industry. Committed to innovation, product excellence, and customer success, Veeva serves more than 1,000 customers, ranging from the world’s largest pharmaceutical companies to emerging biotechs. As a Public Benefit Corporation, Veeva is committed to balancing the interests of all stakeholders, including customers, employees, shareholders, and the industries it serves. For more information, visit

Forward-looking Statements
This release contains forward-looking statements, including the market demand for and acceptance of Veeva’s products and services, the results from use of Veeva’s products and services, and general business conditions, particularly within the life sciences industry. Any forward-looking statements contained in this press release are based upon Veeva’s historical performance and its current plans, estimates, and expectations, and are not a representation that such plans, estimates, or expectations will be achieved. These forward-looking statements represent Veeva’s expectations as of the date of this press announcement. Subsequent events may cause these expectations to change, and Veeva disclaims any obligation to update the forward-looking statements in the future. These forward-looking statements are subject to known and unknown risks and uncertainties that may cause actual results to differ materially. Additional risks and uncertainties that could affect Veeva’s financial results are included under the captions, “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations,” in the company’s filing on Form 10-Q for the period ended July 31, 2021. This is available on the company’s website at under the Investors section and on the SEC’s website at Further information on potential risks that could affect actual results will be included in other filings Veeva makes with the SEC from time to time.



Deivis Mercado
Veeva Systems

Interested in learning more about how Veeva can help?